BUDGET IMPACT ANALYSIS OF APREMILAST ON MODERATE TO SEVERE PSORIASIS IN SPAIN

被引：0
|
作者：
Vanaclocha, F. [1 ]
Carrascosa, J. M. [2 ]
Caloto, T. [3 ]
Elias, I [4 ]
Echave, M. [4 ]
Tencer, T. [5 ]
机构：
[1] 12 Octubre Univ Hosp, Dept Dermatol, Madrid, Spain
[2] Germans Trias & Pujol Univ Hosp, Dept Dermatol, Barcelona, Spain
[3] Celgene Corp, Dept Econ, Madrid, Spain
[4] Pharmacoecon & Outcomes Res Iberia, Madrid, Spain
[5] Celgene Corp, Warren, NJ USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.559
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS35
引用
收藏
页码：A421 / A421
页数：1
相关论文
共 50 条
  • [1] BUDGET IMPACT OF APREMILAST FOR MODERATE TO SEVERE PLAQUE PSORIASIS IN THE UK
    Mughal, F.
    Damera, V
    Gagnon, J.
    VALUE IN HEALTH, 2016, 19 (07) : A564 - A564
  • [2] BUDGET IMPACT ANALYSIS OF APREMILAST IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE
    Solakidi, A.
    Tzanetakos, C.
    Kourlaba, G.
    Maniadakis, N.
    VALUE IN HEALTH, 2018, 21 : S424 - S425
  • [3] COST-UTILITY ANALYSIS OF APREMILAST FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN SPAIN
    Carrascosa, J. M.
    Vanaclocha, F.
    Caloto, T.
    Echave, M.
    Oyaguez, I
    Tencer, T.
    VALUE IN HEALTH, 2015, 18 (07) : A420 - A420
  • [4] Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece
    Avgerinou, Georgia
    Bassukas, Ioannis
    Chaidemenos, Georgios
    Katsampas, Andreas
    Kosmadaki, Marita
    Kousoulakou, Hara
    Petridis, Athanasios
    Schenkel, Brad
    Sotiriadis, Dimitrios
    Spiliopoulos, Theofanis
    Stavropoulos, Panagiotis
    Toumpi, Evgenia
    Xaplanteris, Loukas
    BMC DERMATOLOGY, 2012, 12
  • [5] BUDGET IMPACT ANALYSIS OF APREMILAST IN PATIENTS WITH PSORIASIS IN THE ITALIAN SETTING
    Barbieri, M.
    Capri, S.
    Oskar, B.
    VALUE IN HEALTH, 2015, 18 (07) : A421 - A421
  • [6] Apremilast for the management of moderate to severe plaque psoriasis
    Vangipuram, Ramya
    Alikhan, Ali
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (04) : 349 - 360
  • [7] BUDGET IMPACT ANALYSIS OF APREMILAST IN PATIENTS WITH PSORIATIC ARTHRITIS IN SPAIN
    Almodovar, R.
    Gozalez, C. M.
    Caloto, T.
    Elias, I
    Oyaguez, I
    Tencer, T.
    VALUE IN HEALTH, 2015, 18 (07) : A646 - A646
  • [8] BUDGET IMPACT ANALYSIS OF USTEKINUMAB FOR THE TREATMENT OF MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS IN THAILAND
    Tangwongsiri, D.
    Leartsakulpanitch, J.
    VALUE IN HEALTH, 2012, 15 (07) : A679 - A679
  • [9] BUDGET IMPACT ANALYSIS OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE
    Gourzoulidis, G.
    Rigopoulos, D.
    Kountouris, V
    Christou, P.
    Tzanetakos, C.
    VALUE IN HEALTH, 2019, 22 : S422 - S422
  • [10] BUDGET IMPACT ANALYSIS OF BIMEKIZUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE
    Koulentaki, M.
    Tzanetakos, C.
    Stratigos, A.
    Sotiriou, E.
    Ladha, I
    Kountouris, V
    Relakis, J.
    Kourlaba, G.
    VALUE IN HEALTH, 2022, 25 (12) : S185 - S185
12345